Production (Stage)
Kairos Pharma, Ltd.
KAPA
$0.5232
$0.050210.61%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -78.08% | -43.65% | -207.98% | -147.04% | -106.97% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | 191.30% | 139.29% | 300.00% | -54.17% | -87.22% |
| Total Other Non-Cash Items | -57.77% | -62.98% | -- | -- | -- |
| Change in Net Operating Assets | -289.85% | -359.69% | -283.81% | 163.58% | 327.63% |
| Cash from Operations | -3,864.00% | -4,982.72% | -3,762.96% | 112.69% | 158.69% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -54.67% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 723.76% | 8.24% | -24.86% | -87.78% | -84.17% |
| Cash from Financing | 1,973.53% | 1,308.00% | 1,506.49% | -624.44% | -209.14% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,228.08% | 442.73% | 835.38% | -38.82% | -265.10% |